AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease.

ABSTRACT:

Background

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer and one of the most common cancers. While survival for localized ccRCC is good, the survival of metastatic disease is not, and thirty percent of patients with ccRCC develop metastases during follow-up. Although current scoring methods accurately identify patients at low progression risk, a small subgroup of those patients still experience metastasis. We therefore aimed to identify ccRCC progression biomarkers in "low-risk" patients who were potentially eligible for adjuvant treatments or more intensive follow-up.

Methods

We assembled a cohort of ccRCC patients (n  = 443) and identified all "low-risk" patients who later developed progressing tumors (n  = 8). Subsequently, we performe

SUBMITTER: Nakken S 

PROVIDER: S-EPMC8686242 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature